Approval extends RYBREVANT FASPRO’s well-established, dual-targeted benefit beyond lung cancer SAN DIEGO, Nov. 6, 2026 /PRNewswire/ — Halozyme Therapeutics, Inc. (Nasdaq: HALO) (Halozyme) today announced that Johnson & Johnson was granted accelerated approval from the U.S. Food and Drug…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
